ストックスクリーナーアプリを入手
5.76
4.16%
0.23
アフターアワーズ：
5.76
Kazia Therapeutics Limited Adr (KZIA) 最新ニュース
SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow
Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq
Ratios in Focus: Analyzing Kazia Therapeutics Limited ADR (KZIA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Kazia Therapeutics Stock Scheduled to Reverse Split on Monday, October 28th (NASDAQ:KZIA) - Defense World
Paxalisib shows promise in brain metastasis treatment - Investing.com
It makes sense and dollars to buy Kazia Therapeutics Limited ADR (KZIA) stock - SETE News
Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan
Kazia Therapeutics Limited ADR (KZIA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
China Vanke Co., Ltd. (OTCMKTS:CHVKY) Short Interest Update - Defense World
Kazia Therapeutics (NASDAQ:KZIA) Stock Price Down 3.6% - Defense World
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium - StockTitan
The Psychology of Kazia Therapeutics Limited ADR Inc. (KZIA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Financial Health Report: Kazia Therapeutics Limited ADR (KZIA)’s Ratios Tell a Tale - The Dwinnex
Take off with Kazia Therapeutics Limited ADR (KZIA): Get ready for trading - SETE News
Did Kazia Therapeutics Limited ADR (KZIA) perform well in the last session? - US Post News
Daily Progress: Kazia Therapeutics Limited ADR (KZIA) Drop -5.25, Closing at 0.35 - The Dwinnex
Kazia secures exclusive license for cancer therapy - Investing.com
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER - StockTitan
Pfizer (NYSE:PFE) and Kazia Therapeutics (NASDAQ:KZIA) Critical Comparison - Defense World
Kazia Therapeutics Limited ADR (KZIA) stock analysis: A comprehensive overview - US Post News
Kazia Therapeutics Limited ADR (KZIA) Stock: A Year of Highs and Lows - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) is a good investment, but the stock may be undervalued - US Post News
Kazia Therapeutics Limited ADR Inc. (KZIA) Price Performance: A Technical Analysis Perspective - The InvestChronicle
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GR - GuruFocus.com
Investing in Kazia Therapeutics Limited ADR (KZIA) might be a great opportunity, but the stock is a bit undervalued - US Post News
Kazia Therapeutics Limited ADR (KZIA)’s Day in Review: Closing at 0.40, Up by 3.90 - The Dwinnex
Healthy Upside Potential: Kazia Therapeutics Limited ADR (KZIA) - SETE News
Analytical Overview: Kazia Therapeutics Limited ADR (KZIA)’s Ratios Tell a Financial Story - The Dwinnex
The Kazia Therapeutics Limited ADR (KZIA) had a good session last reading, didn’t it? - US Post News
OppFi Inc (OPFI)’s results reveal risk - US Post News
Kazia Therapeutics Limited ADR Inc. (KZIA) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
There is no way Kazia Therapeutics Limited ADR (KZIA) can keep these numbers up - SETE News
KZIA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
What Analysts Were Expecting After Kazia Therapeutics Limited ADR (NASDAQ: KZIA) rose 15.50% - Stocks Register
Closing Strong: Kazia Therapeutics Limited ADR (KZIA) Ends at 0.32, Down -7.80 from Last Close - The Dwinnex
Kazia Therapeutics Limited ADR (KZIA) can make a big difference with a little luck - SETE News
Was there any good news for Kazia Therapeutics Limited ADR (KZIA) stock in the last session? - US Post News
In the Green: Kazia Therapeutics Limited ADR (KZIA) Closes at 0.40, Up/Down -3.38 from Previous Day - The Dwinnex
Short Interest in Kazia Therapeutics Limited (NASDAQ:KZIA) Increases By 7,076.2% - Defense World
Stock Market Recap: Kazia Therapeutics Limited ADR (KZIA) Concludes at 0.42, a 15.59 Surge/Decline - The Dwinnex
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics - InvestorPlace
Wall Street Analyst Initiated Kazia Therapeutics Limited ADR [KZIA]. What else is Wall St. saying - The DBT News
Kazia Therapeutics Limited ADR (KZIA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Closing Figures: Kazia Therapeutics Limited ADR (KZIA)’s Negative Finish at 0.53, Down -11.48 - The Dwinnex
Kazia Therapeutics (NASDAQ:KZIA) and Organogenesis (NASDAQ:ORGO) Head to Head Review - Defense World
Analyzing Organogenesis (NASDAQ:ORGO) & Kazia Therapeutics (NASDAQ:KZIA) - American Banking and Market News
Kazia Therapeutics Limited ADR (KZIA) Stock: Navigating a Year of Volatility - The InvestChronicle
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):